SCHEMBL23998612

SCHEMBL23998612

Oc1ccn2nc(-c3ccco3)cc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 5/20 0.44
MAPK1 P28482 2/20 0.43
ABCB1 P08183 3/20 0.43
ADORA2A P29274 3/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
L3MBTL1 Q9Y468 5/20 0.41
RECQL P46063 4/20 0.41
KDM4E B2RXH2 4/20 0.41
POLB P06746 4/20 0.41
TDP1 Q9NUW8 4/20 0.41
CTDSP1 Q9GZU7 3/20 0.41
MCL1 Q07820 2/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
TDP2 O95551 1/20 0.41
PKM P14618 2/20 0.40
ALDH1A1 P00352 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23998453 0.84 PTGS1 (0.44) PTGS1MAPK1ABCB1ADORA2AADORA2B
SCHEMBL23998402 0.84 PTGS1 (0.50) PTGS1ABCB1ADORA2AADORA2BADORA1
SCHEMBL23998389 0.83 KDM4E (0.49) PTGS1MAPK1MEN1KMT2AL3MBTL1
SCHEMBL2749356 0.77 APOBEC3A (0.46) PTGS1MAPK1ABCB1ADORA2AADORA2B
SCHEMBL23998387 0.75 ALDH1A1 (0.56) ADORA2AADORA2BADORA1MEN1KMT2A
SCHEMBL23998104 0.75 KDM4E (0.49) ABCB1ADORA2AADORA2BADORA1MEN1
SCHEMBL23998589 0.72 CYP19A1 (0.48) MAPK1MEN1KMT2AL3MBTL1KDM4E
SCHEMBL23998222 0.71 ALDH1A1 (0.43) PTGS1ABCB1ADORA2AADORA2BADORA1
SCHEMBL23998469 0.70 NPC1 (0.41) ADORA2AADORA2BADORA1L3MBTL1POLB
SCHEMBL31692767 0.69 CYP19A1 (0.47) ADORA2AKDM4ETDP2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010947-A Antagonists of adenosine A2a receptors 阿道尔克斯治疗有限公司 2026-05-12 CN disclosed
US-20230203041-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203041-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
CN-115996929-A Antagonists of adenosine A2a receptors 阿道尔克斯治疗有限公司 2023-04-21 CN disclosed
WO-2021224636-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR AdoRx Therapeutics Limited (GB) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203041-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 PTGS1 739/4885MAPK1 3688/4885ABCB1 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.